News | May 30, 2024
Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center
Greg was also central to the planning, design, and construction of this facility
Greg was also central to the planning, design, and construction of this facility
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
EBITDA before special items falls 1.3 percent to € 4.41 billion
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
Subscribe To Our Newsletter & Stay Updated
